(Screening Only) Viral Status HNSCC and CC only: S ites should submit and document prior HPV status and subtype, particularly HPV16 and HPV18, within 28 days of dosing. Tetanus booster (administered 3-7 days prior to Cycle 1 Day 1 at screening; a tetanus booster does not have to be administered if the participant received a tetanus booster within 6 weeks of starting study drug) Revised Protocol No.: 04 Date: 31-May-2019 108 Approved 5.0 v Approved 1.0 v Clinical Protocol CA021002 BMS-986226 anti-ICOS Table 9.4.4-1: Clinical Laboratory Tests Other Analyses Pregnancy test (women of childbearing potential only: screening, pre-dose, discharge). Follicle-stimulating hormone (screening only for women only) 9.4.5 Imaging Safety Assessment Any incidental findings of potent ial clinical relevance that are not directly associated with the objectives of the protocol s hould be evalu ated and handled by the study investigator as per standard medical/clinical judgment.